Ziqiang Yuan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ziqiang Yuan has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Agnes Miller
1 shared publicationAnna Bennett
1 shared publicationB. Legendre
Departments of Transgenomic Inc, Omaha, Nebraska, USA
1 shared publicationBenjamin Legendre
1 shared publicationChristina Lowes
1 shared publicationD.Q. Cai
Joint Laboratory for Regenerative Medicine, Chinese University of Hong Kong-Ji Nan University, Department of Biomedical Engineering, Ji Nan University, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 1 April 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 102
Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis
Bone metastases are frequent complications of breast cancer. Recent literature implicates multiple chemokines in the formation of bone metastases in breast cancer. However, the molecular mechanism of metastatic bone disease in breast cancer remains unknown. We have recently made the novel observation of the BST2 protein expression in human breast cancer cell lines. The purpose of our present study is to investigate the expression and the role of BST2 in bone metastatic breast cancer.
- 1 April 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 102
Open AccessUp-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis
Bone metastases are frequent complications of breast cancer. Recent literature implicates multiple chemokines in the formation of bone metastases in breast cancer. However, the molecular mechanism of metastatic bone disease in breast cancer remains unknown. We have recently made the novel observation of the BST2 protein expression in human breast cancer cell lines. The purpose of our present study is to investigate the expression and the role of BST2 in bone metastatic breast cancer.
- 22 October 2008
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 17 (1) , 16-21
Upregulation of Activator Protein-4 in Human Colorectal Cancer With Metastasis
The aim of this study is to investigate the expression of AP-4, VEGF, and MMP-9 genes in human colorectal cancer. The expression pattern of activator protein-4 in 160 colorectal cancer compared with 32 colorectal adenomas and 32 normal colorectal tissues is demonstrated by tissue microarray-immunohistochemistry and real-time reverse transcriptase—polymerase chain reaction. Apoptosis status using terminal deoxynucleotidyl transferase—mediated dUTP nick-end labeling by comparing activator protein-4 positive versus activator protein-4 negative colorectal cancer is also assessed. The messenger RNA levels of vascular endothelial growth factor and matrix metalloproteinase-9 expression in activator protein-4 positive and negative colorectal cancer were measured using real-time reverse transcriptase— polymerase chain reaction. The activator protein-4 expression in normal colorectal tissue, adenoma, and adenocarcinoma were 4 of 32, 8 of 32, and 78 of 160, respectively. It is shown that the activator protein-4 expression was significantly correlated with the progression of colorectal cancer (P < .01) and differentiation and lymph node metastasis (P < .01). Our results also presented that the activator protein-4 expression was associated with the expression of matrix metalloproteinase-9 and vascular endothelial growth factor in the advanced colorectal cancer.
- 22 October 2008
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 17 (1) , 16-21
Upregulation of Activator Protein-4 in Human Colorectal Cancer With Metastasis
The aim of this study is to investigate the expression of AP-4, VEGF, and MMP-9 genes in human colorectal cancer. The expression pattern of activator protein-4 in 160 colorectal cancer compared with 32 colorectal adenomas and 32 normal colorectal tissues is demonstrated by tissue microarray-immunohistochemistry and real-time reverse transcriptase—polymerase chain reaction. Apoptosis status using terminal deoxynucleotidyl transferase—mediated dUTP nick-end labeling by comparing activator protein-4 positive versus activator protein-4 negative colorectal cancer is also assessed. The messenger RNA levels of vascular endothelial growth factor and matrix metalloproteinase-9 expression in activator protein-4 positive and negative colorectal cancer were measured using real-time reverse transcriptase— polymerase chain reaction. The activator protein-4 expression in normal colorectal tissue, adenoma, and adenocarcinoma were 4 of 32, 8 of 32, and 78 of 160, respectively. It is shown that the activator protein-4 expression was significantly correlated with the progression of colorectal cancer (P < .01) and differentiation and lymph node metastasis (P < .01). Our results also presented that the activator protein-4 expression was associated with the expression of matrix metalloproteinase-9 and vascular endothelial growth factor in the advanced colorectal cancer.
- 31 December 2006
- Published by Elsevier in Cancer Detection Prevention
- Vol. 30 (4) , 333-340
A novel mutation detection approach of hMLH1 and hMSH2 genes for screening of colorectal cancer
- 31 December 2006
- Published by Elsevier in Cancer Detection Prevention
- Vol. 30 (4) , 333-340
A novel mutation detection approach of hMLH1 and hMSH2 genes for screening of colorectal cancer